Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia.
Hematology/Oncology Fellowship Program, University of Washington, Seattle, WA.
Colin D
CD
Godwin
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and.|Division of Gastroenterology, Department of Medicine.
George B
GB
McDonald
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and.|Division of Hematology, Department of Medicine, and.|Department of Epidemiology, University of Washington, Seattle, WA.
Roland B
0000-0002-9268-3341
RB
Walter
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006504:Hepatic Veno-Occlusive Disease / Q000139:chemically induced / Q000453:epidemiology / Q000378:metabolism; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism; D008297:Male; D063268:Sialic Acid Binding Ig-like Lectin 3 / Q000037:antagonists & inhibitors*
D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; C571163:CD33 protein, human; D063268:Sialic Acid Binding Ig-like Lectin 3